京新药业(002020.SZ):拟斥资2.05亿元收购沙溪制药100%股权 打造沙溪凉茶、康复新液等中药大品种
格隆汇12月15日丨京新药业(002020.SZ)公布,2021年12月14日,公司召开第七届董事会第二十八次会议,审议通过了《关于收购广东沙溪制药有限公司100%股权暨关联交易的议案》,同意公司以自有资金2.05亿元收购元金健康持有的广东沙溪制药有限公司(简称“沙溪制药”)99%股权及京新控股持有的沙溪制药1%的股权。该次交易构成关联交易。
沙溪制药主要从事中成药的研发、生产和销售,是商务部首批“中华老字号”企业;独家产品“沙溪凉茶”被列入广东省和国家非物质文化遗产名录。经过多年培育,沙溪制药已发展成拥有先进的生产、检验设备,全面符合GMP标准的现代化中药企业,较好达成公司并购条件
公司已通过元金健康间接持有沙溪制药39.44%的股权,该次收购沙溪制药100%股权的交易,可有效整合公司中药产业资源,综合利用品牌、文化、渠道优势,打造沙溪凉茶、康复新液等中药大品种,实现已有中药业务的积极发展,符合公司中药板块产业发展规划、有利于进一步提升公司总体经营业绩,实现公司的可持续发展。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.